Tenderwize
Retour à la recherche

Open-house rebate agreement for Aclidiniumbromid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 492 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aclidiniumbromid, ATC R03BB05

55/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

55 / 100

Complexité

48 / 100

Facteurs de risque

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

The notice limits participation to pharmaceutical companies and requires a signed declaration of reliability plus suppo...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive pharmaceutical rebate agreement for the active substance Aclidiniumbromid (ATC R03BB05).
  • Open-house model with identical, non-individually negotiable contract terms for all eligible pharmaceutical companies.
Afficher le résumé complet

This is an open-house pharmaceutical rebate agreement for Aclidiniumbromid (ATC R03BB05) led by AOK Bayern. It is not a competitive award procedure: all interested pharmaceutical companies meeting the stated eligibility conditions may join on identical, non-negotiable terms. The contract period runs from 01.03.2026 to 29.02.2028, with contract entry possible until 03.01.2028. Submission is via DTVP or by signed paper originals; German language is required, and non-German documents must include a German translation.

Risques

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

The notice limits participation to pharmaceutical companies and requires a signed declaration of reliability plus suppo...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Aclidiniumbromid

Single lot open-house supply agreement for pharmaceutical rebate contracts concerning Aclidiniumbromid, ATC R03BB05. The lot is framework-like/open-house in nature, with no selection among bidders and identical contract terms for all eligible pharmaceutical companies. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 03, 2028

Détails de la procédure

Date de publication
13 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
25404-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30